

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

Detroit 562

RRID:CVCL_1171

Type: Cell Line

Proper Citation

RRID:CVCL_1171

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1171

Proper Citation: RRID:CVCL_1171

Description: Cell line Detroit 562 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pharyngeal squamous cell carcinoma

Defining Citation: [PMID:77569](#), [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:5668122](#), [PMID:6220172](#), [PMID:6401685](#), [PMID:6500159](#), [PMID:6988327](#), [PMID:10760816](#), [PMID:12124801](#), [PMID:15197768](#), [PMID:18973137](#), [PMID:20215515](#), [PMID:21868764](#), [PMID:22460905](#), [PMID:24201445](#), [PMID:25275298](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26754630](#), [PMID:27397505](#), [PMID:29156801](#), [PMID:29423072](#), [PMID:30877674](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OPC-22 oral and pharyngeal cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Detroit 562

Synonyms: DETROIT 562, Detroit-562, Detroit562, DETROIT562, Det 562, Det. 562, Det562, D562

Cross References: BTO:BTO_0000834, CLO:CLO_0002752, EFO:EFO_0002170, CLDB:cl1035, CLDB:cl1036, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-138, ATCC:CRL-7919, BCRC:60119, BCRJ:0076, BioGRID_ORCS_Cell_line:686, BioSample:SAMN03473286, BioSample:SAMN10988307, cancercellines:CVCL_1171, CCRID:3101HUMTCHu231, Cell_Model_Passport:SIDM00831, ChEMBL-Cells:ChEMBL3308486, ChEMBL-Targets:ChEMBL1075432, CLS:300399, Cosmic:686974, Cosmic:906837, Cosmic:921830, Cosmic:1006472, Cosmic:1017788, Cosmic:1041673, Cosmic:1339917, Cosmic:1752763, Cosmic:2043891, Cosmic:2296294, Cosmic-CLP:906837, DepMap:ACH-000207, ECACC:87042205, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10723-110A3, GDSC:906837, GEO:GSM301580, GEO:GSM827340, GEO:GSM886977, GEO:GSM888046, GEO:GSM1374461, GEO:GSM1374462, GEO:GSM1643590, GEO:GSM1669730, IARC_TP53:2327, IGRhCellID:Detroit562, IZSLER:BS TCL 16, LiGeA:CCLE_046, LINCS_LDP:LCL-1226, PharmacDB:Detroit562_288_2019, PRIDE:PXD002486, PRIDE:PXD030304, Progenetix:CVCL_1171, PubChem_Cell_line:CVCL_1171, Wikidata:Q54831001

ID: CVCL_1171

Record Creation Time: 20220427T215817+0000

Record Last Update: 20260905T175228+0000

Ratings and Alerts

No rating or validation information has been found for Detroit 562.

Warning: Discontinued: ATCC; CRL-7919

Population: Caucasian., Part of: OPC-22 oral and pharyngeal cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Nguyen TT, et al. (2026) NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. *Molecular cancer therapeutics*, 25(8), 1231.

Xu C, et al. (2026) HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization. *Oncogene*, 45(2), 278.

Kelley VM, et al. (2026) Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition. *Cancer research*, 86(9), 2301.

Qin C, et al. (2026) RNA sequencing-based evaluation of the mechanisms underlying the liensinine-mediated inhibition of hypopharyngeal cancer proliferation. *The Journal of international medical research*, 54(2), 3000605261419604.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. *Cell reports. Medicine*, 7(2), 102578.

Wang G, et al. (2026) Trim15 stabilizes VDAC3 via ubiquitination to suppress autophagy and enhance chemosensitivity in hypopharyngeal squamous cell carcinoma. *Cell death discovery*, 12(1), 88.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Zhai PL, et al. (2025) Multi-omics analysis identifies a liquid-liquid phase separation-related subtypes in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1509810.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Orsolic M, et al. (2025) Combined inhibition of EGFR and FGFRs with Cetuximab and Infigratinib showed effectiveness and relevance in proliferation and migration of HNSCC cell lines. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(7), 167940.

Saleh H, et al. (2024) KH-like Domains in PARP9/DTX3L and PARP14 Coordinate Protein-Protein Interactions to Promote Cancer Cell Survival. *Journal of molecular biology*, 436(4), 168434.

Chan C, et al. (2024) Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0. *Molecular cancer therapeutics*, 23(9), 1317.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Mahieu CI, et al. (2024) ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma. *Molecular cancer research : MCR*, 22(2), 152.

Schulz D, et al. (2024) Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy. *Molecular oncology*, 18(2), 431.

Kanwal M, et al. (2024) Aspartate α -hydroxylase Regulates Expression of Ly6 Genes. *Journal of Cancer*, 15(5), 1138.

Waas M, et al. (2024) Molecular correlates for HPV-negative head and neck cancer engraftment prognosticate patient outcomes. *Nature communications*, 15(1), 10869.

Thierry S, et al. (2023) TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization. *Microbial cell (Graz, Austria)*, 10(6), 117.

Hoffmann F, et al. (2023) CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma. *Clinical epigenetics*, 15(1), 112.